AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/coms2/summary_0286-24758447_ITM" title="Facts and information about Milnacipran, Likely the First Drug Approved Specifically for Fibromyalgia, Will Significantly Enlarge The Current Market; Sales of Milnacipran and Duloxetine Will Drive the Fibromyalgia Drug Market From 2002 to 2012, According to a New Study from Decision Resources.">Milnacipran, Likely the First Drug Approved Specifically for Fibromyalgia, Will Significantly Enlarge The Current Market; Sales of Milnacipran and Duloxetine Will Drive the Fibromyalgia Drug Market From 2002 to 2012, According to a New Study from Decision Resources.</a>

Close Set up an RSS feed that alerts you when new articles from PR Newswire are available.

Frequently asked questions about RSS feeds

Milnacipran, Likely the First Drug Approved Specifically for Fibromyalgia, Will Significantly Enlarge The Current Market; Sales of Milnacipran and Duloxetine Will Drive the Fibromyalgia Drug Market From 2002 to 2012, According to a New Study from Decision Resources.

PR Newswire

| October 22, 2003 | COPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

WALTHAM, Mass., Oct. 22 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the fibromyalgia drug market will undergo significant growth with the anticipated launch of milnacipran, the first drug to be specifically indicated for the disease. The new Pharmacor study entitled Fibromyalgia finds that milnacipran, given its higher price point, promising efficacy, and first-to-market status, will have a major impact on the growth of a market currently dominated by older, more inexpensive drugs.

The study also found that along with milnacipran, duloxetine will…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Broad Prevalence, High Unmet Clinical Need, and a Favorable Competitive...: Press release article from: PR Newswire January 31, 2005 700+ words
Decision Resources, Inc., one of the world's leading...care issues, finds that the pain drug market offers biopharmaceutical companies...30 million in the G7 markets. The Decision Resources' pain portfolio will offer a variety...


Pain Drug Market Offers Biopharmaceutical Companies Significant Commercial...: Press release article from: PR Newswire September 9, 2004 700+ words
...therapeutic area director for Pain at Decision Resources. "Decision Resources' pain studies offer objective research...tremendous commercial opportunity in the pain drug market." The Decision Resources' pain portfolio will offer a variety...


Pharmacia and Pfizer's Celebrex and Merck's Vioxx Will Soon Compete with...: Press release article from: PR Newswire September 12, 2001 700+ words
...a new study from Decision Resources, Inc., explains why the OA drug market remains open to innovation...services available from Decision Resources that evaluate the...and development. Decision Resources, Inc., is a world...


Metabolic disease drug market to grow from $9 bn in 2001 to $14 bn in 2007,...: News wire article from: Asia Africa Intelligence Wire March 10, 2003 700+ words
...Press Release) Decision Resources Inc forecasts that the metabolic disease drug market will display robust...publications from Decision Resources entitled DR Pipeline...dominated the metabolic drug market for diseases such...


The $30 Billion Metabolic Syndrome Drug Market Offers Great Commercial...: Press release article from: PR Newswire January 12, 2005 700+ words
...PRNewswire/ -- Decision Resources, Inc., one of...metabolic syndrome drug market, which includes...United States, Decision Resources introduces the Metabolic...epidemiology at Decision Resources. Decision Resources...


Decision Resources Reports Clopidogrel Sales Likely to Dominate the Restenosis...: Press release article from: PR Newswire April 7, 2000 700+ words
...PRNewswire/ -- Decision Resources, Inc., announces...for the restenosis drug market will have occurred...dresources.com Decision Resources, Inc., is a world...network of experts, Decision Resources offers its clients...


Avastin will be primary driver in ovarian cancer drug market, says Decision...: Newspaper article from: Pharma Marketletter October 31, 2005 700+ words
According to a new report from Decision Resources, a USA-based research and advisory firm focusing on pharmaceutical and health care issues, Genentech/Roche's Avastin...


HIV Drug Market to Grow to More Than $8 Billion by 2013; However, Social and...: Press release article from: PR Newswire April 28, 2004 700+ words
...April 28 /PRNewswire/ -- Decision Resources, Inc., one of the world...issues, forecasts that the HIV drug market will grow to more than $8 billion...Raja, Ph.D., analyst, Decision Resources. "Pharmaceutical manufacturers...


Dermatology Drug Market Will Experience Modest Growth of 8% Per Year Through...: Press release article from: PR Newswire August 30, 2004 700+ words
...Aug. 30 /PRNewswire/ -- Decision Resources, Inc., one of the world...that the overall dermatology drug market (which includes atopic dermatitis...Heather Martin, analyst at Decision Resources. "By 2008, as a result of...


Celgene to Dominate the Multiple Myeloma Drug Market Through 2011; Promise of...: Press release article from: PR Newswire April 9, 2003 700+ words
...PRNewswire/ -- Decision Resources, Inc., one of...multiple myeloma (MM) drug market through 2011. Celgene...Paramore, analyst at Decision Resources. The study also...About Pharmacor from Decision Resources Pharmacor is a unique...

For more facts and information, see all results

Source: HighBeam Research, Milnacipran, Likely the First Drug Approved Specifically for...

The AccessMyLibrary advertising network includes: